Clinical Trial Update: Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating dual-dose aprepitant to reduce postoperative nausea and vomiting in patients undergoing laparoscopic bariatric surgery; the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Nausea and Vomiting

Drugs mentioned

• Aprepitant (aprepitant)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Postoperative Nausea and Vomiting, Bariatric Surgery | Phase 4 | Status: TERMINATED